View Older Stories View More Recent Stories
-
S&P Global completes spin-off of Mobility Global Inc.
-
New Era Energy & Digital names new CEO and expands leadership team
-
BridgeBio raises $1 billion in convertible preferred equity
-
FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
-
Florida's Wildlife Corridor Is Turning Five! Live Wildly Celebrates with a New Interactive Map Showing How Greater Conservation Inside the Corridor Can Bring Billions in Benefits
-
SMX Offers National Footprint for Plastic Recycling Proof as U.S. Market Moves From Promises to Verification
-
Sidney Resources Corporation Appoints Former Idaho Governor C.L. "Butch" Otter as Chairman of the Board
-
ServiceNow jumps 4% as Guggenheim flips from Neutral to Buy
-
Unicycive Therapeutics (UNCY) PT Lowered to $13 at Benchmark on OLC Rejection
-
Dave (DAVE) PT Raised to $475 at Benchmark: 'Likely to Have Another Leg Up'
-
Hims and Hers (HIMS) PT Raised to $40 at Canaccord
-
Court awards Klarna's PriceRunner $1.97B in Google antitrust case
-
DeFi Development (DFDV) PT Lowered to $4.70 at Cantor Fitzgerald: Has an Edge
-
Deutsche Bank Starts Brightstar Lottery (BRSL) at Buy
-
Bitmine Immersion Technologies (BMNR) PT Lowered to $30.30 at Cantor Fitzgerald
-
Realty Income (O) Reiterated at Neutral by Cantor Fitzgerald as New JV Announced
-
General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
-
From Claims To Proof: How GORE TEX(R) Products Are Independently Verified
-
Surgery Partners (SGRY) Reiterated at Overweight by Cantor Fitzgerald
-
Universal Health Services (UHS) Reiterated at Neutral by Cantor Fitzgerald: Set-up Difficult
-
Tenet Healthcare (THC) Reiterated at Overweight by Cantor Fitzgerald on Consensus Cut
-
H.C. Wainwright Reiterates Buy Rating on Solitario Exploration & Royalty (XPL)
-
H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)
-
H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
-
HCA Healthcare (HCA) Reiterated at Overweight by Cantor Fitzgerald on Attractive Set-up
-
H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU)
-
H.C. Wainwright Reiterates Buy Rating on Niagen Bioscience (NAGE)
-
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
-
Viking Therapeutic (VKTX) Reiterated at Overweight by Cantor Fitzgerald
-
Jones Trading Starts FTAI Infrastructure (FIP) at Buy
-
Marriott and Coca-Cola strike global beverage supply agreement
-
707 Cayman Holdings board approves AI and blockchain platform study
-
INmune Bio files CORDStrom patent in U.S. after favorable PCT opinion
-
Vertical Research Partners Starts Honeywell Aerospace Inc (HONA) at Hold
-
iBio reports preclinical data on IBIO-610 Activin E antibody in obese NHPs
-
FAA certifies Gogo Galileo HDX for Gulfstream G650 aircraft
-
Seer wins EU patent case, ITC probes Nanomics over IP claims
-
Guardian Metal Resources (GMET:LN) PT Lowered to GBP3.25 at BMO Capital
-
National Grid Ventures buys 35% stake in Joulent for $1.75bn
-
Bausch + Lomb survey links dry eye treatment to emotional wellbeing
-
Samsung Bioepis relaunches eye disease biosimilar with Harrow in the US
-
Silvercorp Metals Inc. (SVM:CN) (SVM) PT Lowered to Cdn$20 at BMO Capital
-
MBA Mortgage Applications 0% vs 1% Prior
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
Germany's ePA Rollout Puts Europe's Health-Data Supply Chain to the Test, Black Book Provider Pulse Finds
-
Fox River Issues Shares Pursuant to Exploration Agreement in Connection with Impending Arrangement
-
ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution
-
Design Therapeutics (DSGN) Reiterated at Overweight by Cantor Fitzgerald
-
H.C. Wainwright Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
-
H.C. Wainwright Reiterates Buy Rating on Septerna Inc (SEPN)
